Abeona Therapeutics Inc. (NASDAQ: ABEO)

Abeona Therapeutics Inc., often recognized by its stock symbol ABEO, is a company specializing in the development of cell and gene therapies for life-threatening diseases. Operating within the biopharmaceutical industry, the company's operations span across various countries, with a significant presence in the United States.

Abeona's primary business activities revolve around the creation and development of cell and gene therapies for a range of diseases. These include recessive dystrophic epidermolysis bullosa (RDEB), CLN1 disease (infantile Batten disease), and Rett Syndrome, among others. The company's main products are its investigational autologous, COL7A1 gene-corrected epidermal sheets, known as prademagene zamikeracel (pz-cel), and its AIM capsid technology, a platform of AAV capsids capable of widespread central nervous system gene transfer.

The company's revenue is generated primarily from its development of these novel therapies. Pz-cel is a significant product in development, while the AIM capsid technology serves as a platform for the creation of various therapeutic indications. Abeona's competitive advantage lies in its leadership position in commercial-scale cell and gene therapy manufacturing, its strong intellectual property protection strategy, and its ability to develop novel in-vivo gene therapies using its AIM capsid technology.

In terms of its position within the industry, Abeona is a leader in the development of cell and gene therapies for life-threatening diseases. The company's AIM capsid technology is a proprietary platform that has been licensed from the University of North Carolina at Chapel Hill. This technology, combined with Abeona's comprehensive manufacturing process, enables the company to enhance supply chain control, establish tighter quality control testing, increase supply capacity, reduce production costs, and gain manufacturing efficiency for clinical trials.

Abeona's customers include Taysha Gene Therapies, Inc., which has exclusively sublicensed the company's CLN1 disease and Rett Syndrome patent families. The company has also licensed its patent families to other institutions, including Stanford University and the University of Edinburgh.

The brand names and trade names of Abeona's products and services include prademagene zamikeracel (pz-cel) and the AIM capsid technology. These products and technologies are at the forefront of Abeona's mission to create, develop, manufacture, and deliver cell and gene therapies to transform the lives of people impacted by life-threatening diseases.